SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

CELC

Celcuity Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The earnings miss is immaterial for a pre-revenue biotech, the stock will trade on the VIKTORIA-1 data readout and the July 17 PDUFA date. Monitor ASCO 2026 presentation on June 2 for detailed efficacy/safety data, which could further derisk the sNDA path. The expanded VIKTORIA-2 study adds first-line optionality, extending the addressable market.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$137.68
T+0 close · May 14, 2026 · via day close
Latest settled
−36.00%
T+60 · $88.11
Vs SPY
−40.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $137.68entry
  2. T+1 · 6mo ago −3.99%α −3.93% · $132.18
  3. T+5 · 6mo ago +0.40%α −0.56% · $138.23
  4. T+20 · 5mo ago −35.91%α −38.03% · $88.24
  5. T+60 · 3mo ago −36.00%α −40.52% · $88.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity reported Q1 2026 GAAP EPS of -$0.97, a 9.0% miss vs consensus of -$0.89, with net loss widening to $52.8M from $37.0M a year ago. The key catalyst is the positive Phase 3 VIKTORIA-1 topline data in the PIK3CA mutant cohort, supporting an sNDA submission in Q3 2026 ahead of the July 17 PDUFA date for the wild-type NDA. The stock's move will be driven by the clinical progress and regulatory timeline, not the earnings miss, as the company remains pre-revenue.

Key Financial Metrics

EPS
−$0.97
est −$0.89 · -9.0%
Rating
miss

Key Facts

  • GAAP EPS -$0.97 vs consensus -$0.89 (9.0% miss); net loss $52.8M vs $37.0M YoY
  • Phase 3 VIKTORIA-1 PIK3CA mutant cohort met primary endpoint with statistically significant PFS improvement vs alpelisib
  • FDA Priority Review for gedatolisib NDA in PIK3CA wild-type ABC; PDUFA date July 17, 2026
  • sNDA submission for PIK3CA mutant cohort planned for Q3 2026
  • Cash, equivalents, and investments of $387.1M expected to fund operations through 2027
  • VIKTORIA-2 expanded to include Study 2 evaluating gedatolisib as first-line treatment in endocrine-sensitive HR+/HER2- ABC

Financial Impact

Net loss widened by $15.8M YoY to $52.8M; operating expenses increased 40% to $50.5M driven by commercial launch preparation

net lossoperating expensescash burn

Risk Factors

  • FDA could issue a Complete Response Letter (CRL) on July 17, delaying or denying approval
  • Commercial launch costs will accelerate cash burn; need for additional financing before 2027
  • Competitive landscape includes Novartis's Piqray and other PI3K/AKT/mTOR inhibitors

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295313

Track record

26 reports on CELC

Performance horizon

6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026